Search Results - Kyoungah See

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis by Elsie Grace, Orin Goldblum, Lisa Renda, Noah Agada, Kyoungah See, Craig Leonardi, Alan Menter

Connect to this object online.

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses by Richard B. Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg

Connect to this object online.

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab... by Melinda Gooderham, Ronald Vender, Jeffrey Crowley, H. Chih-Ho Hong, Meghan Feely, Alyssa Garrelts, Kyoungah See, Bruce Konicek, Lawrence Green

Connect to this object online.

Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks by Alexander Egeberg, Lars Erik Kristensen, Luis Puig, Phoebe Rich, Saxon D. Smith, Alyssa Garrelts, Kyoungah See, Thorsten Holzkaemper, Konstantinos Fotiou, Christopher Schuster

Connect to this object online.

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-Wo... by April Armstrong, Alvaro González-Cantero, Saakshi Khattri, Guilherme Muzy, William N. Malatestinic, Anastasia Lampropoulou, Meghan Feely, Sophia Kyoungah See, Can Mert, Andrew Blauvelt

Connect to this object online.

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by... by Alexander Egeberg, Jason E. Hawkes, Najwa Somani, Russel Burge, Kyoungah See, Gaia Gallo, Missy McKean-Matthews, Melinda Gooderham, George Han, April Armstrong

Connect to this object online.

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)... by Jennifer Soung, Jennifer C. Cather, Melinda Gooderham, Caitriona Ryan, Najwa Somani, Meghan Feely, Kyoungah See, Russel Burge, Mohamed Elrayes, Gaia Gallo, April W. Armstrong

Connect to this object online.